Thoracic Oncology
Research activity is centered on non-small cell lung cancer, with emphasis on previously untreated advanced NSCLC and disease settings defined by KRAS G12C mutation. The sponsor’s clinical portfolio reflects a focused interest in targeted approaches for advanced lung malignancies.
- Advanced NSCLC
- KRAS G12C-mutant lung cancer
- Previously untreated disease
Clinical research in this area is directed toward patients with metastatic and unresectable lung cancer requiring mutation-specific treatment strategies.
Targeted Cancer Therapy
The sponsor is engaged in development work around KRAS G12C-directed therapy and combination treatment strategies in solid tumours. Its clinical interest includes pairing targeted agents with EGFR inhibition to address oncogenic signalling in lung cancer.
- KRAS G12C inhibition
- Combination oncology regimens
- EGFR-targeted therapy
This area of research aligns with precision oncology for molecularly defined cancers.
Oncology Safety and Tolerability
Clinical interest extends to the safety and tolerability of investigational cancer treatments in advanced lung cancer populations. The sponsor’s work includes evaluation of treatment-related adverse effects and overall clinical acceptability in patients with advanced disease.
- Safety assessment
- Tolerability evaluation
- Advanced cancer populations
These studies support the clinical development of therapies intended for use in metastatic oncology settings.
Clinical Pharmacology
Research activity also includes pharmacokinetics in the setting of combination oncology treatment, with attention to how investigational agents behave when used together in patients with advanced lung cancer. This supports characterization of exposure and treatment behavior in a targeted therapy context.
- Pharmacokinetics
- Combination treatment exposure
- Advanced lung cancer
The sponsor’s clinical research landscape is concentrated on molecular oncology and treatment optimization for KRAS-driven disease.
